
From Misdiagnosis to Mission: How One Man's Ordeal Became a Blueprint for Perseverance
Opinions expressed by Entrepreneur contributors are their own.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
When Dean Gregorie first developed a small hump below his neck at age sixteen, few paid it any mind. His mother, though, saw more. Weight gain. The round face. The bone-deep fatigue. To her, it spelled something far more complex: Cushing's disease. But when she voiced her concerns, doctors smiled politely and waved them off.
"Teenagers gain weight," they said.
What followed was not just a lapse in judgment; it was a decades-long system failure. Dean became the unseen patient. The ignored anomaly. No one had time to read the story. But like any great founder building something against the odds, he—and his tenacious family—refused to give up.
Seeing What Others Miss
The early symptoms were dismissed with lazy diagnoses: poor diet, lack of exercise, and normal adolescence. But Helen Gregorie was relentless. She scoured medical journals. Dug through case studies. Her instincts shouted, "Cushing's." But doctors, operating within conventional playbooks, refused to explore a rare diagnosis. In startup parlance, they ignored the outlier data, clinging to averages instead of curiosity.
Dean was a patient who was overlooked not because of ambiguity, but because of predictability. If he had been a product, he would've been shut down in beta without anyone reading the specs.
The Burn Cost of Delay
Over the next two decades, Dean cycled through over fifty medical professionals. His symptoms worsened: purple striations, skyrocketing blood pressure, relentless fatigue. And yet the narrative never changed. "Lifestyle," they told him.
Imagine pitching the same idea to dozens of venture capitalists, each one dismissing it for a reason you know isn't true. Dean wasn't lazy or noncompliant. He was fighting a disease no one bothered to look for.
Still, he climbed the corporate ladder in the automotive coatings industry. He earned promotions. He delivered results. But his body was breaking. And behind every workday win, there was a night spent battling exhaustion, shame, and the creeping belief that maybe it really was his fault.
A Systemic Breakdown
By 2013, his body sent a blunt memo: collapse. Dean landed in the ICU with diabetic ketoacidosis. An endocrinologist was consulted, but not to solve the underlying mystery—just the emergency. Despite glaring signs—signs his family had documented in detail—no one ordered a test for Cushing's. Even after introducing a second endocrinologist, even after infections ravaged his system, even as his skin tore in a workplace fall, nothing changed.
It wasn't until 2019 that a single primary care physician broke the inertia. He reviewed his whole history, acknowledged the pattern, and ordered the cortisol tests that would finally unveil the truth: Cushing's disease. Twenty-three years after it all began.
Recovery Is Not Linear
The tumor was removed in 2020. But there was no triumphant return, no swift rebound. Recovery was glacial. Dean's body, once flooded with cortisol, was suddenly starved of it. Cortisol had to be administered by medication. Energy flatlined. Nights stretched long and restless. Then came the back pain, unrelenting and tied to years of untreated structural damage.
"There wasn't a morning I woke up feeling better," Dean says. "There were just mornings I woke up and decided to try again."
Sound familiar? Founders know this rhythm. Recovery isn't always exponential growth; it's the grind. The grit. The decision to show up despite the metrics still being red.
Turning Pain into Platform
This book, Surviving Cushing's Disease: A Young Man's Journey, is Dean's first act of advocacy. Not a TED Talk. Not a foundation. Just this: a deeply personal, unapologetic account of what it means to be invisible in a system designed to treat averages, not anomalies.
In its pages, the symptoms of Cushing's—unexplained weight gain, thinning skin, recurrent infections—are given shape and language. Not to diagnose, but to awaken awareness. Dean's story is not a callout. It's a call forward.
Startups, Survivors, and Second Opinions
Entrepreneurs can draw from Dean's journey as much as patients can:
Follow the fringe data : When something feels off—even if others don't see it—pursue it.
: When something feels off—even if others don't see it—pursue it. Pressure test the system : Experts are invaluable. But they are not infallible.
: Experts are invaluable. But they are not infallible. Leverage the pain: Your hardest chapters may become your most powerful pages.
Because sometimes, the most resilient visionaries don't wear lanyards or give keynotes. They survive in silence for years. Then one day, they write.
And someone else learns how to speak up.
Click here for Amazon
Website: https://tales2btold.com/
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Yahoo
3 hours ago
- Yahoo
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Yahoo
3 hours ago
- Yahoo
Major update on plan to slash prescription medications to $25 for millions
The federal government will introduce legislation to parliament to cap the cost of Pharmaceutical Benefits Scheme (PBS) prescriptions to $25 this week. The cost-of-living move was one of Labor's major election promises and will save Aussies $200 million per year. Once passed, eligible medicines would be lowered from $31.60 to $25 from January 1 next year. Pensioners and concession cardholders will continue to pay just $7.70 for their prescriptions until at least 2030. Prime Minister Anthony Albanese said the cap was an example of cost-of-living relief that helped 'every Australian'. RELATED Major update on $5,520 HECS cash boost for millions to lift them out of debt Major warning after Aussie receives random $350 payment in her bank account Aussie 'appalled' by $4,000 ATO tax bill after common deductions rejected 'The size of your bank balance shouldn't determine the quality of your healthcare. My government will continue to deliver cost-of-living relief for all Australians,' he said. Health Minister Mark Butler said the move meant medicines would be their cheapest in decades. 'Cheaper medicines are good for the hip pocket and good for your health,' he said. 'For general patients, medicines haven't been this cheap since 2004." The change would lower the price of medicines by more than 20 per cent and follows an earlier round of price reductions in 2023. The government previously cut the maximum price of a PBS script from $42.50 to $30. The bill comes after US President Donald Trump flagged tariffs of up to 200 per cent on pharmaceuticals earlier this month. Pharmaceuticals are one of Australia's biggest exports to the US. According to the UN's Comtrade database, Australia exported $2.2 billion in products to the US last year. The Australian government has said it is not willing to trade away or do deals on the PBS. How will the cheaper medicines work? The PBS is the government subsidy program that allows Australians to get a wide range of prescription medicines at more affordable prices. There are two main prices for PBS medicines. The general rate is what applies to most people and is what would be lowered from $31.60 to $25. The concessional rate applies to concession-card holders and is currently frozen at $7.70 until 2030. There are more than 900 medicines on the PBS schedule, spread across more than 5,000 brands. You can check if your medication is on the PBS here.